about
Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5Beyond CA125: the coming of age of ovarian cancer biomarkersModification by ubiquitin-like proteins: significance in apoptosis and autophagy pathwaysSUMO Ubc9 enzyme as a viral targetIdentification and characterization of proteins that selectively interact with the LHR mRNA binding protein (LRBP) in rat ovariesUbc9 expression predicts chemoresistance in breast cancer.Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner.Viral manipulation of the cellular sumoylation machinery.Sumoylation of human argonaute 2 at lysine-402 regulates its stability.SUMOylation modulates the function of Aurora-B kinaseGold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation.Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro.An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation.LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1Autophagy regulates UBC9 levels during viral-mediated tumorigenesis.Quantitative analysis of multi-protein interactions using FRET: application to the SUMO pathwayIt takes two to tango: Ubiquitin and SUMO in the DNA damage response.Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts.Human pathogens and the host cell SUMOylation system.Starting and stopping SUMOylation. What regulates the regulator?SUMO rules: regulatory concepts and their implication in neurologic functions.SUMO pathway components as possible cancer biomarkers.Dual role for SUMO E2 conjugase Ubc9 in modulating the transforming and growth-promoting properties of the HMGA1b architectural transcription factor.Identification of interconnected markers for T-cell acute lymphoblastic leukemiaSumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.
P2860
Q24317074-818C0F5F-D169-40BC-9230-FDA361CCC6BCQ24320248-77FB83EB-073A-4C92-A92F-0ACF8FDDF6E0Q24651567-212637E4-7C53-4B13-B75A-5787633A8C7FQ27011543-65826A03-356C-40F3-8C3C-57EE6A09ED2AQ28305355-3B35C85B-1CE2-4324-84BC-FA2BB5B205DBQ28570225-F38250A0-DB9A-4DAA-8C63-D1D117901A71Q33579371-EA5B0683-4B94-4264-9665-B280707E66B6Q33753966-45AAC3C9-8A6E-4015-8ACD-D85A2829828FQ33910635-F06BB279-7AF5-4568-8737-B74E0285E03FQ33921588-84C01EAA-163E-4C43-A555-6036358C4018Q34043389-8F2AC44B-45B7-4050-B456-8A5207FC27D8Q34184043-2ACFA18F-00B5-43DE-B62E-09F5D07B838FQ34346747-1600E946-3F8C-4767-9B92-31F50FEBF552Q34678197-1982140B-F73E-4274-A3A8-1DA462260554Q35861199-382AE4D8-D044-491D-941A-4E5672A05586Q36295602-ECD10D3A-5DE1-4F95-A4CA-A992C6FF3E5BQ36503296-9F57D7B5-E760-4B55-B691-511027D85BA1Q36917433-36594886-C57B-4A85-9A62-C408A1DBBE7FQ37349403-94211641-CE7A-4357-A377-9ED4A2E5EB00Q37954599-36F6457B-01DA-4E1E-9D42-FD9C2DECFD25Q38118140-6C033BF2-C056-4C82-B371-6BDCBD3B2BE0Q38132691-AE670E2F-27DD-4E44-831D-CC13B87CEFF6Q38515816-96E89B7B-9BF9-4B63-B96F-59B9C2C4943CQ40160836-A7A6EAD6-AA5C-442B-A792-1DFD0C9ADC7AQ41969078-D0DC6453-DE21-4AB5-9A1A-A023183F3925Q42066873-7120E111-8B38-44D9-80BC-67AE81E2D493
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Targeting Ubc9 for cancer therapy.
@ast
Targeting Ubc9 for cancer therapy.
@en
type
label
Targeting Ubc9 for cancer therapy.
@ast
Targeting Ubc9 for cancer therapy.
@en
prefLabel
Targeting Ubc9 for cancer therapy.
@ast
Targeting Ubc9 for cancer therapy.
@en
P2860
P1476
Targeting Ubc9 for cancer therapy.
@en
P2093
Stergios J Moschos
Yin-Yuan Mo
P2860
P304
P356
10.1517/14728222.9.6.1203
P407
P577
2005-12-01T00:00:00Z